InnoCare Announces Approval of Orelabrutinib for the First-line Treatment of CLL/SLL in China

InnoCare Announces the Acceptance of New Drug Application for pan-TRK Inhibitor Zurletrectinib in China

InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

InnoCare Releases 2024 Results and Business Highlights

InnoCare Announces First Patient Dosed in the Phase III Registrational Trial of ICP-488 for the Treatment of Psoriasis in China

InnoCare 2024 Annual Results Earnings Call

Data of InnoCare's ICP-488 for the Treatment of Psoriasis Presented at Late Breaking Oral Presentation of 2025 AAD

Data of InnoCare's Orelabrutinib for the Treatment of MS Released at 2025 ACTRIMS Forum

InnoCare Announces the Approval of Registrational Phase III Study of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Treatment of CLL/SLL Patients in China

InnoCare and KeyMed Jointly Announce the License Agreement with Prolium for CD20xCD3 Bispecific Antibody ICP-B02

Together towards the Future

Latest Data of InnoCare’s Orelabrutinib Presented at the 66th Annual Meeting of ASH